Table 1. Six-Year EFS Rates According to Total Pathologic Complete Response and Hormone Receptor Status.
| Hormone Receptor Status | tpCR (n = 202) | Residual Disease After Neoadjuvant Treatment (n = 389)a | HR (95% CI) | ||
|---|---|---|---|---|---|
| Patients, No. | 6-y EFS, %b | Patients, No. | 6-y EFS, %b | ||
| Overall | 202 | 82 | 389 | 56 | 0.33 (0.23-0.47) |
| ER-positive | 71 | 88 | 231 | 61 | 0.24 (0.12-0.50) |
| ER-negative | 131 | 79 | 158 | 48 | 0.32 (0.20-0.49) |
| ER-positive and/or PgR-positive | 75 | 88 | 243 | 59 | 0.25 (0.13-0.49) |
| ER-positive and PgR-positive | 49 | 85 | 170 | 64 | 0.35 (0.16-0.76) |
| ER-positive and PgR-negative | 22 | 95 | 61 | 52 | 0.07 (0.01-0.55) |
| ER-negative and PgR-positive | 4 | 75 | 12 | 30 | 0.27 (0.03-2.17) |
| ER-negative and PgR-negative | 126 | 79 | 144 | 50 | 0.33 (0.21-0.52) |
| Unknown | 1 | NA | 2 | NA | NA |
Abbreviations: EFS, event-free survival; ER, estrogen receptor; HR, hazard ratio; NA, not available; PgR, progesterone receptor; tpCR, total pathologic complete response.
a
Includes patients withdrawn before surgery.
b
Event-free survival rates were estimated using the Kaplan-Meier method.